Unknown
NA
INTERVENTIONAL
NCT05487469
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Rheumatic heart disease usually accompanied by weakened immune function. And the cardiopulmonary bypass further aggravating the decline of immune function. Therefore, the prevention of Postoperative immune function collapse is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 will Improve the immune function and prognosis of patients.
Interventions
Name:
Thymosin Alpha1
Type:
DRUG
Description:
Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
Name:
Blank Control
Type:
OTHER
Description:
the Control group did not receive Thymosin alpha 1 or any placebo.
Primary Outcomes
Measure:
The highest Sequential Organ Failure Assessment (SOFA) score of 5 days after surgery
TimeFrame:
5 days after surgery
Description:
Trial Information
NCT ID
NCT05487469
Status
Unknown
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Nanjing Medical University
Last Updated
December 15, 2025